v3.26.1
ACQUISITIONS - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 27, 2026
USD ($)
treatment
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Apr. 30, 2026
USD ($)
Feb. 28, 2026
USD ($)
Dec. 31, 2025
Business Combination [Line Items]                
Intangible asset amortization   $ 73,492 $ 4,846 $ 77,975 $ 9,693      
Stock-based compensation expense   $ 75,695 $ 47,531 $ 119,152 $ 85,231      
Nonrecurring Adjustment, Acquisition-Related Cost                
Business Combination [Line Items]                
Acquisition related costs $ 47,100              
Stock-based compensation expense 13,000              
Commitment fee amount $ 22,800              
5.5% senior unsecured notes due in February 2034 (the 2034 Notes) | Senior Notes                
Business Combination [Line Items]                
Debt instrument, aggregate principal amount             $ 850,000  
Debt stated interest rate   5.50%   5.50%     5.50% 5.50%
Amicus Therapeutics                
Business Combination [Line Items]                
Number of treatment therapies acquired | treatment 2              
Total consideration $ 5,323,561              
Acquisition related costs   $ 30,400   $ 32,800        
Intangible asset amortization   69,000   69,000        
Inventory step-up 228,000              
Amortization of acquired inventory step-up   $ 11,700   $ 11,700        
Lease liabilities 53,800              
Right-of-use assets $ 46,100              
Amicus Therapeutics | Measurement Input, Discount Rate | IPR&D - BMN 820                
Business Combination [Line Items]                
Intangible asset, measurement input 0.125              
Amicus Therapeutics | Measurement Input, Discount Rate | Commercialized Pharmaceutical Products                
Business Combination [Line Items]                
Intangible asset, measurement input 0.120              
Amicus Therapeutics | 5.5% senior unsecured notes due in February 2034 (the 2034 Notes) | Senior Notes                
Business Combination [Line Items]                
Debt instrument, aggregate principal amount             $ 850,000  
Debt stated interest rate             5.50%  
Amicus Therapeutics | Senior Secured Term Loan Facility | Line of Credit | Secured Debt                
Business Combination [Line Items]                
Debt instrument, aggregate principal amount           $ 2,800,000